The loss or mutation of PTEN is a common feature in many types of cancers, including breast cancer, prostate cancer, and glioblastoma. PTEN dysfunction leads to the activation of the PI3K/AKT pathway, promoting cell survival, growth, and proliferation. Therefore, assessing PTEN status in histological samples can provide valuable insights into the aggressiveness and potential treatment strategies for cancer.
